AbbVie Bid for Biotech Could Expand with Experimental Drug
AbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Timing conversions into stablecoins can protect gains during drawdowns. This piece outlines indicators and decision points for choosing pivots.
10,055 articlesAbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Dutch Bros has shown rapid growth in recent years. This investing guide breaks down how the company wins customers, w...
Three practical lessons from SpaceX’s IPO can guide investors as Anthropic and OpenAI approach the market. Learn how ...
Palantir tumbles about 7% midday as Palo Alto Networks and CrowdStrike hold steadier, raising questions about governm...
Intel faces renewed pressure as AMD gains share in the server CPU market, driven by AI workloads. This guide explains...
Nvidia announces a breakthrough that isn’t a chip, signaling a new era for AI infrastructure. Investors react as data...
Two consumer-facing stocks sit at a crossroads: GameStop is tightening its turnaround with a leaner footprint, while ...
Record Prime Day spending climbs, yet the average purchase shrinks. The pattern signals growing financial pressure on...
Celebrity fashion moments can become financial talking points. This guide explains how to evaluate, insure, and sell ...
As discounts surge through the warm months, shoppers and investors gain a rare window to save on essentials and stake...
IBM unveils a groundbreaking 0.7nm nanostack in a research setting, reiterating it will not become a chipmaker. The m...
Investors watched the barnes noble education stock surge as earnings signals mixed. This guide breaks down what drove...